Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

961.58 -4.91 (-0.51%)
Streaming Delayed Price Updated: 9:35 AM EDT, May 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2021
Upgrades For Nutrien Ltd (NYSE: 
Via Benzinga
Is Now The Time To Buy Stock In Tesla, GM Or Regeneron?
One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why I... 
Via Benzinga
Intellia Seeks To Raise $400M Via Equity
Intellia Therapeutics Inc (NASDAQ: NTLA) commenced an underwritten public offering of $400 million shares of its common stock. Underwriters have an option to... 
Via Benzinga
Facebook And Nvidia Lead The QQQ Higher Monday
The Nasdaq was trading sharply higher throughout Monday’s session amid a rebound in growth and tech names. The Inve... 
Via Benzinga
Ignoring Monday's 2 Big Nasdaq Winners Could Cost You Serious Money
Find out why these stocks are climbing higher. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Why Intellia Therapeutics Stock Is Skyrocketing Today
The company reported promising interim trial results for its CRISPR gene-editing candidate. 
Via The Motley Fool
Intellia Stock Leads Biotech Rally On Historic Moment For CRISPR
Intellia led a rally for CRISPR stocks on Monday on early promise for its gene-editing drug. The news sent NTLA stock to a record high. 
Via Investor's Business Daily
Why Intellia Therapeutics Stock Is Soaring Today
Intellia Therapeutics Inc (NASDAQ:NTLA) is trading signifi... 
Via Benzinga
Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks
Gene editing stocks, led by NTLA stock, are powering higher on Monday following a landmark announcement by Intellia Therapeutics. 
Via InvestorPlace
Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate
Intellia Therapeutics Inc (NASDAQ: NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced positive interim data from an ongoing Phase 1... 
Via Benzinga
Sanofi - Regeneron's Immunotherapy Scores European Approval For Skin And Lung Cancer Settings
The European Commission (EC) has approved Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo (cemiplimab) for two... 
Via Benzinga
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
3 Companies With Low Debt to Buy in Case Interest Rates Rise
These companies are generating tons of free cash and don't need to rely on debt to grow. 
Via The Motley Fool
Dual-Antibody Cocktail Shows Effectiveness In COVID-19 Animal Models: Reuters
In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against a wide range of COVID-19 variants, Reuters reported ... 
Via Benzinga
Exposures COVID-19
3 Bargain Stocks You Can Buy Today
The market is mispricing these names, ignoring the long-term growth prospects ahead for each of them. 
Via The Motley Fool
How This Pharma Company Can Benefit From Its Competitors
Delays in FDA approval for Incyte could spell good news for Sanofi. 
Via The Motley Fool
Exposures Product Safety
Healthcare Portfolio Playbook: Time To Rebalance With MedTech
As we look to re-balance our portfolio in the near-term, investors should consider adding Medtech as we have suggested in the past. Though, more recently, we have also focused on large-cap... 
Via Talk Markets
BioNTech Starts Dosing In Mid-Stage Melanoma Vaccine Trial
BioNTech SE (NASDAQ: BNTX) has dosed the first patient in its Phase 2 trial evaluating the BNT111 cancer vaccine. The study evaluates the therapeutic cancer... 
Via Benzinga
Biden Administration Devotes Over $3.2B For Development Of Oral Antiviral Therapies For COVID-19: CNBC
Officials on Thursday announced that the Biden Administration plans to invest more than $3.2 billion in developing antiviral medicines to treat COVID-19 and other... 
Via Benzinga
Exposures COVID-19
Cramer Gives His Opinion On Bank of America, Advanced Micro Devices And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said Martin Marietta Materials, Inc. (NYSE: MLM) is a well-run company. He likes the stock because it doesn't... 
Via Benzinga
Elanco Is Looking To Challenge Zoetis, Will The $440 Million Kindred Buyout Help?
Elanco Animal Health said Wednesday it would buy Kindred Biosciences for roughly $440 million, sending KIN stock soaring. 
Via Investor's Business Daily
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,... 
Via Benzinga
Exposures COVID-19 Product Safety
Regeneron Antibody Treatment Cuts Risk Of Death In Some Critical COVID-19 Patients, Large-Scale Study Finds
Regeneron Pharmaceutical Inc.’s (NASDAQ: REGN) COVID-19 monoclonal antibody cocktail reduced the risk of death by 20% in hospitalized COVID-19 patients who have not mounted... 
Via Benzinga
Exposures COVID-19
Clearside Biomedical Shares Soar On Encouraging Safety Profile For Injectable Axitinib In Wet AMD Patients
Clearside Biomedical Inc (NASDAQ: CLSD) has announced positive safety results from Cohort 1 (n=6) of OASIS Phase 1/2a trial of CLS-AX (axitinib injectable... 
Via Benzinga
2 Reasons Why This FDA Decision Could Add Billions to Regeneron's Revenue
They have to do with production -- and delivery to the patient. 
Via The Motley Fool
Exposures COVID-19 Product Safety
Nvidia And Dollar Tree Lead The Nasdaq In A Mixed Day For The Markets
U.S. indices had another mixed day of trading following worse-than-expected U.S. jobless figures and inflation data released Thursday. 
Via Benzinga
Twitter And Regeneron Lead The SPY In Another Mixed Day Of Trading
U.S. indices at a mixed day of trading Wednesday as investors and traders weighed the U.S. 30-Year Treasury note falling to 2.1483%,... 
Via Benzinga
Merck Cuts a Billion-Dollar COVID Deal
The U.S. government will pay $1.2 billion for 1.7 billion doses of Merck's experimental oral COVID-19 drug. 
Via The Motley Fool
Exposures COVID-19
Amazon And Intuit Lead The Nasdaq In A Mixed Day Of Trading
U.S. indices had another mixed day of trading Tuesday as investors weighed a weakened 10-year treasury yield and the IRS chief stating that Congres... 
Via Benzinga
FDA Expands EUA for Lower Dose Subcutaneous Version of Regeneron's COVID-19 Antibody Cocktail
The FDA has authorized a new, lower-dose version of Regeneron Pharmaceuticals Inc’s (NASDAQ: REGN) COVID-19 monoclonal antibody cocktail for those with... 
Via Benzinga
Exposures COVID-19 Product Safety
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.